Concluding another successful year, the 2015 JP Morgan Healthcare Conference has seen its share of announcements, discoveries and unveiling of things to come. Following is a look at some highlights as the conference comes to an end:
– FierceBiotech compiled a target list of ripe biotechnology companies primed for a merger or acquisition in 2015.
– Roche announced that it is partnering with genome pioneer J. Craig Venter in a multi-year deal to sequence and analyze tens of thousands of genomes for the company’s Genentech unit with the goal of identifying new drug targets and biomarkers.
– The Wall Street Journal reported that NIH Director Dr. Francis Collins expressed concern that U.S. funding in innovation is on a dangerous downward trajectory and, if continued, may erode U.S. leadership in drug development.
After four days of the conference, we’ve seen more than 14,000 tweets using #JPM15. TG Therapeutics’ and Bluebird Bio topped the cashtag counts on Wednesday and Thursday, producing 46 tweets each with their cashtags $TGTX and $BLUE.
Some of the most retweeted tweets included:
The shared sentiment of JPMorgan attendees as summarized by John Carroll of FierceBiotech…
Link to full story: http://bit.ly/1C4Vwvh
Pharma execs’ thoughts on how and what technologies will be instrumental in transforming medicine via Meg Tirrell…
TheStreet columnist Adam Feuerstein’s light humor…